Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Emmanuel S. Antonarakis

Oncology
M Health Fairview
Fairview Express Care
2450 Riverside Ave, 
Minneapolis, MN 
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
M Health Fairview
Fairview Express Care
2450 Riverside Ave, 
Minneapolis, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emmanuel Antonarakis is an Oncologist in Minneapolis, Minnesota. Dr. Antonarakis is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Antonarakis is currently accepting new patients.

His clinical research consists of co-authoring 445 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
M Health Fairview University Of Mn
M Health Fairview Southdale Hospital
Languages Spoken
English
French
Greek
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

FAIRVIEW EXPRESS CARE
2450 Riverside Ave, Minneapolis, MN 55454
Call: 612-672-7422

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


11 Clinical Trials

A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer
A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drug: Enoblituzumab
Study Phase: Phase 2
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2025
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Drug: Radium-223
Study Phase: Phase 2
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drugs: Olaparib, Abiraterone acetate, Prednisone
Study Phase: Phase 2
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Enrollment Status: Unknown
Publish Date: May 31, 2023
Intervention Type: Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
A Phase 1b Study of Enzalutamide Plus CC-115 in Men With Castration-Resistant Prostate Cancer (CRPC)
A Phase 1b Study of Enzalutamide Plus CC-115 in Men With Castration-Resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, CC-115
Study Phase: Phase 1
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological, Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 08, 2021
Intervention Type: Biological, Drug
Study Drugs: Radium-223, Sipuleucel-T
Study Phase: Phase 2
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.
A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.
Enrollment Status: Completed
Publish Date: March 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

445 Total Publications

Novel MAML2 Fusions in Human Malignancy.
Novel MAML2 Fusions in Human Malignancy.
Journal: Cancers
Published: August 19, 2025
View All 445 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Gautam G. Jha
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Gautam G. Jha
Hematology Oncology | Hematology | Oncology

Fairview Express Care

14500 99th Ave N, Suite 100, 
Maple Grove, MN 
 (16.1 miles away)
763-898-1000
Languages Spoken:
English, Hindi, Marathi
See accepted insurances
Accepting New Patients
Offers Telehealth

Gautam Jha is a Hematologist Oncology specialist and a Hematologist in Maple Grove, Minnesota. Dr. Jha is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC). Dr. Jha is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arpit Rao
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arpit Rao
Hematology Oncology | Hematology | Oncology
909 Fulton St Se, 
Minneapolis, MN 
 (0.6 miles away)
612-672-7422
Languages Spoken:
English
See accepted insurances

Arpit Rao is a Hematologist Oncology specialist and a Hematologist in Minneapolis, Minnesota. Dr. Rao is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Adult Soft Tissue Sarcoma.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Ian J. Okazaki
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Ian J. Okazaki
Hematology Oncology | Hematology | Oncology

Fairview Express Care

6401 France Ave S, 
Edina, MN 
 (7.1 miles away)
952-924-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Okazaki is a Hematologist Oncology specialist and a Hematologist in Edina, Minnesota. Dr. Okazaki is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Adult Soft Tissue Sarcoma, Wilms Tumor, and Chromophobe Renal Cell Carcinoma. Dr. Okazaki is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Antonarakis's expertise for a condition
ConditionClose
  • Elite
  • Familial Prostate Cancer
    Dr. Antonarakis is
    Elite
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Hormone Replacement Therapy (HRT)
    Dr. Antonarakis is
    Elite
    . Learn about Hormone Replacement Therapy (HRT).
    See more Hormone Replacement Therapy (HRT) experts
  • Prostate Cancer
    Dr. Antonarakis is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Prostatectomy
    Dr. Antonarakis is
    Distinguished
    . Learn about Prostatectomy.
    See more Prostatectomy experts
  • Advanced
  • Bone Tumor
    Dr. Antonarakis is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Antonarakis is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Antonarakis is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Antonarakis is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Orchiectomy
    Dr. Antonarakis is
    Advanced
    . Learn about Orchiectomy.
    See more Orchiectomy experts
  • Renal Cell Carcinoma (RCC)
    Dr. Antonarakis is
    Advanced
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
View All 9 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Antonarakis is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Angiosarcoma
    Dr. Antonarakis is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Bladder Cancer
    Dr. Antonarakis is
    Experienced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Breast Cancer
    Dr. Antonarakis is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Colorectal Cancer
    Dr. Antonarakis is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Endometrial Cancer
    Dr. Antonarakis is
    Experienced
    . Learn about Endometrial Cancer.
    See more Endometrial Cancer experts
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved